uploads/2018/05/neurons-3154919_1280.jpg

How Much Upside Do Analysts Expect from AbbVie?

By

Updated

Company overview

AbbVie (ABBV) is a global biopharmaceutical company that formed after separating from Abbott Laboratories (ABT) in 2013. AbbVie has a strong research focus, and its approach to developing and commercializing advanced therapies is targeted at complex and serious diseases in areas such as the following:

  • chronic autoimmune diseases in rheumatology
  • gastroenterology and dermatology
  • oncology, including blood cancers
  • virology, including hepatitis C (or HCV) and HIV
  • neurological disorders such as Parkinson’s disease
Article continues below advertisement

Analysts’ recommendations

Of the 23 analysts covering AbbVie in May, 11 analysts have given the stock “buy” or higher ratings, 11 have given it “holds,” and one has given it a “sell” rating. The mean rating for the stock is 2.35 with a target price of $115.9, which implies an upside potential of 16.3% over the stock’s closing price of $99.63 on May 8.

Peers’ ratings

Of the total 23 analysts covering Johnson & Johnson (JNJ) in May, 12 analysts have given the stock “buy” or higher ratings. Eight analysts have given it “hold” ratings, and three have given it “sell” or lower ratings. The mean rating for the stock is 2.43, and its target price is $145.

Of the total 22 analysts covering Pfizer (PFE) in May, 11 analysts have given the stock “buy” or higher ratings, nine have given it “hold” ratings, and two have given it “strong sell” ratings. The mean rating for the stock is 2.59, and its target price is $39.89.

Of the 21 analysts covering Merck & Company (MRK) in May, 16 have given the stock “buy” or higher ratings, while five have given it “hold” ratings. The mean rating for the stock is 1.95, and its target price is $68.

In the next part of the series, we’ll take a look at the performances of AbbVie’s key products.

Advertisement

More From Market Realist